Enanta Pharmaceuticals is a clinical-stage biotechnology company whose only commercial revenue currently comes from royalties tied to AbbVie's hepatitis C virus (HCV) treatment MAVYRET/MAVIRET. Those royalties have been shrinking steadily, making quarterly results an important gauge of how long the company's cash can support its drug pipeline. Investors are watching closely because Enanta is pivoting toward immunology and respiratory syncytial virus (RSV) programs that have yet to generate product sales. The fiscal fourth quarter and full-year 2026 results therefore matter less for current profitability and more for the signals they send about cost discipline, cash runway, and the timing of upcoming clinical catalysts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Enanta reported fiscal fourth-quarter 2026 revenue of $12.9 million, down from $15.1 million in the year-ago period and below the FactSet consensus estimate of about $14.6 million. Revenue consists almost entirely of royalties from AbbVie's HCV product sales, which continue to decline.
The company posted a net loss of $23.7 million, or $0.81 per share, compared with a loss of $18.7 million, or $0.87 per share, a year earlier. The loss was wider than the roughly $0.72-per-share consensus loss expected by analysts. Research and development expenses increased to $26.1 million from $23.8 million, reflecting investment in the immunology pipeline.
For the full fiscal year 2026, revenue totaled $63.0 million, down from $65.3 million in fiscal 2025, while the net loss widened to $68.2 million, or $2.35 per share. Enanta also disclosed a workforce reduction of approximately one-third in connection with its cost actions. Management expects its cash, cash equivalents, and marketable securities, together with retained royalty revenue, to fund operations into fiscal 2029.
Enanta shares entered the report under significant pressure, having lost roughly 30% of their value since the start of 2026 while the broader S&P 500 advanced. The stock has also declined more than 18% over the trailing three months, reflecting investor concern about fading HCV royalties and the absence of near-term product revenue. The wider-than-expected quarterly loss and the revenue shortfall are unlikely to improve that sentiment in the short term. However, the company's pipeline readouts, rather than the income statement, have historically driven the stock's most meaningful moves.
The near-term story for Enanta centers on execution across its pipeline rather than quarterly earnings. Management said it expects to complete dosing in the Phase 1 trial of EDP-978, an oral KIT inhibitor being developed for chronic urticaria and other mast cell-driven diseases, by the end of 2026, with data now planned for the first quarter of 2027.
On the virology side, investors will watch for the start of the registrational RESOLVE study of zelicapavir in high-risk adults with RSV, as well as pediatric Phase 2b (LOTUS) data anticipated in 2027. The company is also progressing EPS-3903, an oral STAT6 inhibitor, toward an investigational new drug (IND) filing in the second half of 2026. Financially, the key monitor is the trajectory of AbbVie HCV royalties, which remain the company's only source of revenue.
In my own workflow I frequently turn to Tickeron’s AI Screener when evaluating names like this one. It helps me quickly filter for technical patterns, performance metrics, and industry comparisons that complement the fundamental story. The tool is straightforward to use and gives me a structured view alongside the clinical and cash-flow details I track manually.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ENTA advanced for three days, in 207 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The RSI Indicator entered the oversold zone -- be on the watch for ENTA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
ENTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 52 cases where ENTA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ENTA as a result. In 62 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for ENTA turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 48 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ENTA entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.170) is normal, around the industry mean (3.592). P/E Ratio (-4.545) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.550) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (5.285) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. ENTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of drugs and other pharmaceuticals products
Industry Biotechnology